Hefei Enrit Pharmaceutical Co., Ltd.

Main research purpose: According to the relevant provisions of bioequivalence test, the memantine hydrochloride orodisintegrating tablets (trade name: Memary®, specification: 20 mg) produced by Daiichi Sankyo Co., Ltd. were selected as the reference preparation, and the test preparation memantine hydrochloride orodisintegrating tablets (specification: 20 mg) produced and provided by Hefei Enrui Pharmaceutical Co., Ltd. were subjected to fasting and postprandial human bioequivalence test, to compare whether the absorption rate and degree of the drug in the test preparation were within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under fasting and postprandial administration conditions. Secondary research purpose: To observe the safety of oral administration of the test preparation memantine hydrochloride orodisintegrating tablets (specification: 20 mg) and the reference preparation memantine hydrochloride orodisintegrating tablets (trade name: Memary®, specification: 20 mg) by healthy volunteers.

The main purpose of the study is to evaluate the population pharmacokinetic characteristics of desloratadine citrate oral solution in infants and children with acute and chronic urticaria and allergic rhinitis. The secondary purpose of the study is to evaluate the safety of desloratadine citrate oral solution in the treatment of acute and chronic urticaria and allergic rhinitis in infants and children. The purpose of the exploratory study is to evaluate the effectiveness of desloratadine citrate oral solution in the treatment of acute and chronic urticaria and allergic rhinitis in infants and children.

The main purpose of the study is to study the pharmacokinetic characteristics of the test preparation HY-100209 orodisintegrating tablets and the reference preparation Tamiflu® in healthy adult subjects in the fasting/postprandial state, and to compare the relative bioavailability of the pharmacokinetic parameters AUC and Cmax of the test preparation and the reference preparation. The secondary purpose of the study is to evaluate the safety of the test preparation HY-100209 orodisintegrating tablets and the reference preparation Tamiflu® in healthy adult subjects.